Gold Or Platinum Patents (Class 424/649)
-
Publication number: 20140377336Abstract: The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of glioblastoma multiforme and medulloblastoma. Dianhydrogalactitol acts as an alkylating agent on DNA that creates N7 methylation. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide; the drug acts independently of the MGMT repair mechanism.Type: ApplicationFiled: January 22, 2013Publication date: December 25, 2014Inventors: Dennis Brown, Jeffrey Bacha, Sandra Dunn
-
Publication number: 20140377318Abstract: Methods and systems for killing or inhibiting pathogens present in treatments area including but not limited to the nasal cavity, the vaginal area, and the anal area. The methods feature introducing a substrate with an antimicrobial metal into the treatment area. The substrate may be coated, lined, plated, or clad with the antimicrobial metal, either partially or entirely. Or, the substrate itself may be an antimicrobial metal. Antimicrobial metals include but are not limited to copper, zinc, silver, gold, and certain metal alloys. The step of directly contacting the substrate with antimicrobial metal to the treatment area kills or inhibits present pathogens. The antimicrobial metal may leave a trace amount of residue, which may continue to kill or inhibit pathogens after the system has been removed from the treatment area or penetrate into deeper layers of the treatment area.Type: ApplicationFiled: September 10, 2014Publication date: December 25, 2014Inventor: S. Douglas Cornell
-
Publication number: 20140370005Abstract: The invention relates generally to anti-angiogenesis agents and related methods of using to anti-angiogenesis agents for biomedical applications including direct monotherapy and combination therapy for treatment of an angiogenesis related condition. In an embodiment, the invention provides a class of opioid compounds and structurally related opioid derivatives exhibiting anti-VEGF activity for use in therapeutic procedures, including phototherapy. Opioid compounds and structurally related opioid derivatives of the invention may be administered alone or in combination with administration of a phototherapy agent and/or other therapeutic agent.Type: ApplicationFiled: June 26, 2014Publication date: December 18, 2014Inventors: Gary L. Cantrell, Raghavan Rajagopalan, David W. Berberich, Amolkumar Karwa, Richard B. Dorshow
-
Publication number: 20140370079Abstract: The present application describes a method of inhibiting tumor growth including contacting the tumor with a compound that inhibits activity of RhoJ protein.Type: ApplicationFiled: May 6, 2014Publication date: December 18, 2014Applicant: Korea Advanced Institute of Science and Technology (KAIST)Inventors: Gou Young KOH, Chan Kim, Hanseul Yang, Won Do Heo, Injune Kim, Sangyong Jon, Akiyoshi Uemura
-
Publication number: 20140370121Abstract: Targeting uncontrolled cell proliferation and resistance to DNA damaging chemotherapeutics with at least one reagent has significant potential in cancer treatment. Replication Protein A, the eukaryotic single-strand (ss) DNA binding protein, is essential for genomic maintenance and stability via roles in both DNA replication and repair. Reported herein are small molecules that inhibits the in vitro, in vivo, and cellular ssDNA binding activity of RPA, thereby disrupting the eukaryotic cell cycle, inducing cytotoxicity and increasing the efficacy of chemotherapeutic agents damage DNA, and/or disrupt its replication and/or function. These results provide new insights into the mechanism of RPA-ssDNA interactions in chromosome maintenance and stability. This represents a molecularly targeted eukaryotic DNA binding inhibitor and demonstrates the utility of targeting a protein-DNA interaction as a means of studying the cell cycle and providing a therapeutic strategy for cancer treatment.Type: ApplicationFiled: August 27, 2014Publication date: December 18, 2014Inventors: John J. Turchi, Sarah Shuck
-
Publication number: 20140370122Abstract: The present invention relates to a method of inhibiting growth of a cancerous cell. The method includes the step of exposing the cancerous cell to an anti-cancer therapy and an effective amount of a steroid saponin.Type: ApplicationFiled: September 3, 2014Publication date: December 18, 2014Inventors: Michael John Story, Kenneth Michael Wayte
-
Publication number: 20140370006Abstract: The invention relates generally to anti-angiogenesis agents and related methods of using to anti-angiogenesis agents for biomedical applications including direct monotherapy and combination therapy for treatment of an angiogenesis related condition. In an embodiment, the invention provides a class of opioid compounds and structurally related opioid derivatives exhibiting anti-VEGF activity for use in therapeutic procedures, including phototherapy. Opioid compounds and structurally related opioid derivatives of the invention may be administered alone or in combination with administration of a phototherapy agent and/or other therapeutic agent.Type: ApplicationFiled: June 26, 2014Publication date: December 18, 2014Inventors: Gary L. Cantrell, Raghavan Rajagopalan, David W. Berberich, Amolkumar Karwa, Richard B. Dorshow
-
Publication number: 20140370064Abstract: A film-forming composition comprises a solvent and unimolecular nanoparticles of a self-crosslinkable nanogel star polymer. The nanogel star polymer comprises i) a crosslinked polymer core (nanogel core) and ii) 6 or more independent polymer arms covalently linked to the core by respective first end groups. A plurality of the arms comprise reactive groups for effecting crosslinking of the nanoparticles. An essentially solvent-free film layer comprising the nanoparticles self-crosslinks, optionally assisted by subjecting the film layer to a thermal treatment and/or a photochemical treatment. A surface treated article comprising the crosslinked film layer can effectively inhibit growth of and/or kill Gram-negative microbes, Gram-positive microbes, fungi, and/or yeasts.Type: ApplicationFiled: June 16, 2013Publication date: December 18, 2014Inventors: Victor Y. Lee, Robert D. Miller, Joseph Sly
-
Publication number: 20140363523Abstract: The present invention provides a compound of Formula (I), wherein: each X is independently hydrogen or deuterium; and at least one X is deuterium.Type: ApplicationFiled: January 17, 2013Publication date: December 11, 2014Inventor: Adam Morgan
-
Publication number: 20140363521Abstract: This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of homologous recombination deficiency (HRD) or an HRD signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an HRD signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.Type: ApplicationFiled: April 4, 2014Publication date: December 11, 2014Inventors: Victor Abkevich, Kirsten Timms, Alexander Gutin
-
Publication number: 20140363443Abstract: The present disclosure relates to 2,4-pyrimidinediamines substituted with tricyclic carbamates and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, such as JAK2 or JAK3, is therapeutically useful.Type: ApplicationFiled: August 22, 2014Publication date: December 11, 2014Applicant: Rigel Pharmaceuticals, Inc.Inventors: Rajinder Singh, Somasekhar Bhamidipati, Vadim Markovtsov
-
Publication number: 20140363483Abstract: A method of treating or preventing Helicobacter pylori infection in a subject includes the step(s) of: administering to the subject a composition. The composition has a carbonaceous material and an active particle. The active particle is coated on the carbonaceous material and made of a material selected from the group consisting of silver, gold, aluminum, zinc, copper, and titanium dioxide.Type: ApplicationFiled: September 30, 2013Publication date: December 11, 2014Applicant: Feng Chia UniversityInventor: Tse-Hao KO
-
Publication number: 20140363522Abstract: The present invention concerns methods and compositions for the inhibition or reduction of the primary tumor and metastasis by inhibition of fatty acid binding proteins.Type: ApplicationFiled: May 13, 2014Publication date: December 11, 2014Inventors: Ernst LENGYEL, Kristin NIEMAN, Hilary KENNY
-
Publication number: 20140356456Abstract: This invention relates to methods and compositions for treating pancreatic cancer. More specifically, this invention relates to treating pancreatic cancer with certain ATR inhibitors in combination with gemcitabine and/or radiation therapy. This invention also relates to methods and compositions for treating non-small cell lung cancer. More specifically, this invention relates to treating non-small cell lung cancer with an ATR inhibitor in combination with cisplatin or carboplatin, etoposide, and ionizing radiation.Type: ApplicationFiled: February 28, 2014Publication date: December 4, 2014Inventors: John Robert Pollard, Philip Michael Reaper
-
Publication number: 20140356459Abstract: The invention relates to molecular targets and their use to counteract tumors. Naturally occurring microRNAs that regulate human oncogenes and methods of use thereof are described. Suitable nucleic acids for use in the methods and compositions described herein include, but are not limited to, pri-miRNA, pre-miRNA, mature miRNA or fragments of variants thereof that retain the biological activity of the mature miRNA and DNA encoding a pri-miRNA, pre-miRNA, mature miRNA, fragments or variants thereof, or regulatory elements of the miRNA. The here claimed approach is efficacious also on Cancer Stem Cells.Type: ApplicationFiled: December 11, 2012Publication date: December 4, 2014Inventors: Ruggero De Maria Marchiano, Valeria Coppola, Matilde Todaro, Micol Eleonora Fiori, Enrico Garaci
-
Publication number: 20140356457Abstract: This invention relates to a method of identifying a modulator of an NADPH oxidase, whereby said modulator is suitable as a lead compound and/or as a medicament for the treatment and/or prevention of hearing loss and/or phantom hearing, the method comprising the steps of (a) contacting a test compound with a protein, wherein said protein (i) comprises or consists of the amino acid sequence of any one of SEQ ID NO: 1, 3 or 5, or (ii) is encoded by a nucleic acid comprising or consisting of the sequence of any one of SEQ ID NO: 2, 4, 6, 23 or 24, or (iii) is a fragment of the protein according to (i) or (ii) and exhibits NADPH oxidase activity, or (iv) has a sequence at least 75% identical with the protein according to (i) or (ii) or with the fragment according to (iii) and exhibits NADPH oxidase activity, and optionally with one or more NADPH oxidase subunits, under conditions allowing binding of said test compound to said protein or, if present, said subunit(s); (b) optionally determining whether said test comType: ApplicationFiled: April 7, 2014Publication date: December 4, 2014Applicant: UNIVERSITY OF GENEVAInventors: Karl-Heinz KRAUSE, Botond BANFI
-
Publication number: 20140356458Abstract: The present invention includes embodiments for treatment and/or prevention of sickle cell disease that employ Hydroxyfasudil or Isocoronarin D alone or either in conjunction with each other or an inducer of HbF production. The compounds may act synergistically, and the compounds employed circumvent the side effects seen with Hydroxyurea.Type: ApplicationFiled: September 13, 2012Publication date: December 4, 2014Applicant: KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGYInventors: Magbubah Essack, Vladimir Bajic, Aleksandar Radovanovic
-
Publication number: 20140356455Abstract: Methods of generating cell lines with a sequence variation or copy number variation of a gene of interest, methods of use thereof, and cell lines with a sequence variation or copy number variation of a gene of interest are provided.Type: ApplicationFiled: December 6, 2013Publication date: December 4, 2014Applicants: The Board of Trustees of the Leland Stanford Junior University, Parkinson's InstituteInventors: Renee Ann Reijo Pera, J. William Langston, Birgitt Schule, Theodore D. Palmer, Blake Byers, Ha Nam Nguyen, James Anthony Byrne, Branden John Cord
-
Patent number: 8900565Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of histone deacetylase 8 (HDAC8). Also described herein are methods of using such HDAC8 inhibitors, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of HDAC8 activity.Type: GrantFiled: November 21, 2012Date of Patent: December 2, 2014Assignee: Pharmacyclics, Inc.Inventors: Joseph J. Buggy, Sriram Balasubramanian, Erik Verner, Vincent W. F. Tai, Chang-Sun Lee
-
Publication number: 20140351961Abstract: Disclosed are methods and compositions for treating cancer that involved an isolated double stranded ribonucleic acid (dsRNA) molecule that inhibits the expression of Hsp-27.Type: ApplicationFiled: August 30, 2012Publication date: November 27, 2014Inventor: Alexzander A. Asea
-
Publication number: 20140348854Abstract: The invention provides compositions and methods for utilizing human epididymal secretory protein E4 (HE4) in the prevention and treatment of cancer and other human diseases.Type: ApplicationFiled: June 6, 2012Publication date: November 27, 2014Applicant: WOMEN & INFANTS' HOSPITAL OF RHODE ISLANDInventors: Richard G. Moore, Rakesh K. Singh
-
Publication number: 20140348950Abstract: The present invention relates to the pyrrolidine substituted with flavone derivatives, represented by the compounds of Formula (I) or pharmaceutically acceptable salts, solvates, stereoisomers or diastereoisomers thereof or pharmaceutical compositions containing the compounds of Formula (I) for use in the prevention and/or treatment of oral mucositis caused by cancer therapy such as radiation therapy.Type: ApplicationFiled: January 11, 2013Publication date: November 27, 2014Applicant: PIRAMAL ENTERPRISES LIMITEDInventors: Somesh Sharma, Alan Hatfield, Shivani Acharya
-
Patent number: 8894989Abstract: The present invention relates to tetraaza phenalen-3-one compounds which inhibit poly(ADP-ribose) polymerase (PARP) and are useful in the chemosensitization of cancer therapeutics. The induction of peripheral neuropathy is a common side-effect of many of the conventional and newer chemotherapies. The present invention further provides means to reliably prevent or cure chemotherapy-induced neuropathy. The invention also relates to the use of the disclosed PARP inhibitor compounds in enhancing the efficacy of chemotherapeutic agents such as temozolomide. The invention also relates to the use of the disclosed PARP inhibitor compounds to radiosensitize tumor cells to ionizing radiation. The invention also relates to the use of the disclosed PARP inhibitor compounds for treatment of cancers with DNA repair defects.Type: GrantFiled: June 19, 2012Date of Patent: November 25, 2014Assignee: Eisai Inc.Inventors: Weizheng Xu, Greg Delahanty, Ling Wei, Jie Zhang
-
Patent number: 8895076Abstract: A liquid composition containing a polymer micelle and having a pH values of 3.0 to 7.0 is provided. The micelle is constituted of a coordination compound having a block copolymer of polyethylene glycol and polyglutamic acid and cisplatin that is coordinate-bonded to the block copolymer.Type: GrantFiled: May 27, 2009Date of Patent: November 25, 2014Assignees: Nanocarrier Co., Ltd., The University of TokyoInventors: Kazunori Kataoka, Nobuhiro Nishiyama, Chieko Tsuchiya, Tatsuyuki Hayashi
-
Publication number: 20140341849Abstract: Embodiments of the invention are directed to methods of determining the prognosis of a breast cancer patient by evaluating the activity of the glucocorticoid receptor in tumor cells. Other embodiment include methods of treating breast cancer cells, particularly, chemo-resistant cells, with a glucocorticoid receptor antagonist and an anticancer agent or compound.Type: ApplicationFiled: August 4, 2014Publication date: November 20, 2014Inventors: Deng PAN, Masha Kocherginsky, Suzanne D. Conzen
-
Publication number: 20140341900Abstract: Methods of treating cancers comprising FGFR1 gene amplification are provided. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule in combination with at least one additional therapeutic agent.Type: ApplicationFiled: November 13, 2012Publication date: November 20, 2014Inventors: Thomas Harding, Servando Palencia, Li Long, Kevin Hestir
-
Publication number: 20140342005Abstract: A method for producing triblock copolymer-coated metallic nanoparticle seeds which increases the size and shape homogeneity of the triblock copolymer-coated metallic nanoparticle seeds. A quantity of triblock copolymer-coated metallic nanoparticle seeds. A method for producing triblock copolymer-coated metallic nanoparticles which increases the size and shape homo-geneity of the triblock copolymer-coated metallic nanoparticles. A quantity of triblock copolymer-coated metallic nanoparticles. A method for producing modified metallic nanoparticles which increases the size and shape homogeneity of the modified metallic nanoparticles. A quantity of modified metallic nanoparticles.Type: ApplicationFiled: February 28, 2013Publication date: November 20, 2014Applicant: LOMA LINDA UNIVERSITYInventors: Ralph S. Kurti, JR., Christopher C. Perry, Theodore Sabir
-
Publication number: 20140342019Abstract: Methods preparing a personal care substance in fluid form from gemstones or gold. The gemstones or gold are comminuted and dissolved. Solvent is removed by distillation, leaving an oily residue usable in the personal care substance. The personal care substance may include fulvates and humates, or dissolved gold. The personal care substance may comprise an ozonated oil.Type: ApplicationFiled: May 13, 2014Publication date: November 20, 2014Inventors: Tiffany Andersen, Robert Allen Barlett
-
Publication number: 20140335015Abstract: The present invention relates to novel nanoparticles which can be advantageously used in the health sector as diagnostic and/or therapeutic agents. Nanoparticles of the invention comprise a metallic material at least partly covered with an hafnium oxide material or embedded therein. When compared to existing products, these nanoparticles offer a remarkable benefit over risk ratio. Specifically, these nanoparticles potentiate the efficiency of known metallic nanoparticles. Indeed, they retain the metal intrinsic properties and are now in addition safely usable in a mammal, in particular in a human being. The invention also relates to methods for producing said nanoparticles, to compositions containing same, and to uses thereof.Type: ApplicationFiled: December 17, 2012Publication date: November 13, 2014Inventors: Agnes Pottier, Laurent Levy, Marie-Edith Meyre
-
Publication number: 20140335079Abstract: This disclosure relates to solenopsin derivatives, pharmaceutical compositions, and therapeutic uses related thereto. In certain embodiments, the disclosure relates to compounds of the following formula: or salts, esters or prodrugs thereof as described herein.Type: ApplicationFiled: May 7, 2014Publication date: November 13, 2014Applicants: EMORY UNIVERSITY, UNION UNIVERSITY, MERCER UNIVERSITYInventors: Jack L. Arbiser, J. Philip Bowen, E. Blake Watkins
-
Patent number: 8883737Abstract: Described are methods and compositions for treating epithelial tumors with a folate-vinca conjugate in combination with at least one other chemotherapeutic agent in which the tumors include ovarian, endometrial or non-small cell lung cancer tumors, including platinum-resistant ovarian tumors and platinum-sensitive ovarian tumors.Type: GrantFiled: November 11, 2011Date of Patent: November 11, 2014Assignee: Endocyte, Inc.Inventors: Joseph Anand Reddy, Christopher Paul Leamon
-
Patent number: 8883199Abstract: N-hydroxy-4-{2-[3-(N,N-dimethylaminomethyl)benzofuran-2-ylcarbonylamino]ethoxy}-benzamide of formula (I): or an addition salt thereof with a pharmaceutically acceptable acid or base, alone or in association with surgery, chemotherapy or hormone therapy treatment or radiotherapy, for use in the treatment of cancer, characterized in that it is administered for 4 consecutive days, that period being followed by 3 consecutive days without any administration of compound of formula (I), with the proviso that the chemotherapy is not FOLFOX.Type: GrantFiled: September 6, 2012Date of Patent: November 11, 2014Assignees: Les Laboratoires Servier, Pharmacyclics, Inc.Inventors: Ioana Kloos, Renata Robert, Anne Jacquet-Bescond, Stephane Depil, Marylore Chenel, Sylvain Fouliard, Sriram Balasubramanian
-
Publication number: 20140328931Abstract: The present invention provides, among other things, a particle which includes a core comprised of self-assembled one or more nucleic acid molecules, the core being characterized by an ability to adopt at least two configurations: a first configuration having a first greatest dimension greater than 2 ?m and; a second configuration having a second greatest dimension less than 500 nm, wherein addition of a film coating converts the core from its first configuration to its second configuration. Methods of making and using of provided particles are also disclosed.Type: ApplicationFiled: February 26, 2014Publication date: November 6, 2014Applicant: Massachusetts Institute of TechnologyInventors: Paula T. Hammond, Jong Bum Lee, Young Hoon Roh
-
Publication number: 20140328904Abstract: The present disclosure relates generally to compositions and methods for treating cancer with a glucopyranosyl lipid A (GLA) in the absence of antigen.Type: ApplicationFiled: July 17, 2014Publication date: November 6, 2014Inventors: Carlos V. Paya Cuenca, Jan Henrik Ter Meulen
-
Publication number: 20140328944Abstract: This invention encompasses a novel composition comprising silenced CTBP-1 combined with a compound selected from among 5-FU, Cisplatin and Epirubicin. The invention further relates to a method of treating gastric cancer with a combination of siRNA silenced CTBP-1 and a compound selected from among 5-FU, Cisplatin and Epirubicin.Type: ApplicationFiled: May 2, 2013Publication date: November 6, 2014Inventors: Manuel Gidekel, Carolina Bizama, Osvaldo Podhajcer
-
Publication number: 20140322356Abstract: Embodiments of the present invention concern methods related to treating, prognosticating and/or diagnosing at least brain metastatic breast cancer. Embodiments of the methods include characterizing circulating tumor cells for the presence or absence of EpCAM and, upon identification of EpCAM negative cells and identification of the status of other markers (such as heparanase and/or Notch1, for example), treating the individual based on the determination of the characterization.Type: ApplicationFiled: November 28, 2012Publication date: October 30, 2014Applicant: BAYLOR COLLEGE OF MEDICINEInventors: Dario Marchetti, Lon Ridgway, Lixin Zhang
-
Publication number: 20140322354Abstract: Methods and compositions for the diagnosis, prognosis and classification of cancer, especially colorectal cancer, are provided. For example, in certain aspects methods for cancer prognosis using expression or methylation analysis of selected biomarkers are described. Particular aspects of the present invention may include methods and biomarkers for diagnosing or detecting colorectal cancer or metastasis in a subject by measuring a level of expression of biomarker miRNA such as miR-885-5p in the sample from the subject and evaluating the risk of developing cancer or metastasis in the subject.Type: ApplicationFiled: March 17, 2014Publication date: October 30, 2014Inventors: Ajay GOEL, Keun Hur, Yuki Toiyama, C. Richard Boland
-
Publication number: 20140322355Abstract: Compounds that are fatty acid synthesis modulators are provided. The compounds may be used to treat disorders characterized by disregulation of the fatty acid synthase function by modulating the function and/or the fatty acid synthase pathway. Methods are provided for treating such disorders including viral infections, such as hepatitis C infection, cancer and metabolic disorders.Type: ApplicationFiled: June 25, 2014Publication date: October 30, 2014Applicant: 3-V BIOSCIENCES, INC.Inventors: Johan D. Oslob, Robert S. McDowell, Russell Johnson, Hanbiao Yang, Marc Evanchik, Cristiana A. Zaharia, Haiying Cai, Lily W. Hu
-
Publication number: 20140314664Abstract: Symmetrically and asymmetrically branched homopolymers are modified at the surface level with functional groups that enable forming aggregates with water insoluble or poorly water soluble pharmaceutically active agents (PAA). The aggregates formed are specifically induced by interaction of PAA and homopolymer and are different from aggregates that are formed by the polymer alone in the absence of the PAA or by the PAA alone in the absence of the polymer. Such aggregates can be used to improve drug solubility, stability, delivery and efficacy.Type: ApplicationFiled: January 6, 2012Publication date: October 23, 2014Applicant: ANP Technologies, Inc.Inventors: Dujie Qin, Ray Yin, Jing Pan, Yubei Zhang
-
Publication number: 20140314834Abstract: The present disclosure relates generally to compositions and methods for treating cancer with a glucopyranosyl lipid A (GLA) in the absence of antigen.Type: ApplicationFiled: April 18, 2014Publication date: October 23, 2014Applicant: IMMUNE DESIGN CORP.Inventors: Carlos V. Paya Cuenca, Jan Henrik Ter Meulen
-
Publication number: 20140314878Abstract: The disclosure provides rifamycin and rifamycin derivative compositions, including rifabutin and rifabutin derivative compositions able to cause drug-sensitization in a cancer cell or inhibition of a cancer cell. The disclosure also provides methods of administering such compositions to cancer cells to sensitize them to drugs, such as chemotherapeutics, or directly inhibit them. The disclosure also provides methods of administering such compositions to increase reactive oxygen species (ROS), particularly superoxides, in cancer cells. The disclosure further provides methods of determining whether a cancer will respond to chemotherapeutics and whether to administer rifamycin or a rifamycin derivative based on ROS levels in cancer cells of a patient.Type: ApplicationFiled: July 2, 2014Publication date: October 23, 2014Inventors: James Sacchettini, Niam Zhou, Dwight Baker, Steven A. Maxwell, Deeann Wallis
-
Publication number: 20140308370Abstract: Compositions and methods for determining circulating biomolecules before, during, and/or after treatment of a patient with an anti-cancer or anti-tumor drug (or putative drug) are described. Methods of treatments based on the compositions and methods described herein are also provided. Noninvasive methods and kits are provided for assessing the efficacy of an anti-cancer therapy for killing or damaging cancer cells. Embodiments are used to determine the cancer-killing efficacy of an anti-cancer drug in a patient, to optimize the selection of an anti-cancer drug for treatment of a patient, to adjust the dosage of an anti-cancer drug for treatment of a particular cancer in a patient and for identifying useful anti-cancer therapeutics for any one particular type of cancer.Type: ApplicationFiled: April 15, 2014Publication date: October 16, 2014Inventors: David Frendewey, Gavin Thurston, George D. Yancopoulos, Matthew Koss, Gustavo Droguett
-
Publication number: 20140308342Abstract: The present invention relates to chimeric (preferably, bifunctional) compounds, compositions comprising those compounds and methods of treating cancer in a patient or subject, especially including metastatic cancer where cancer cells exhibit overexpression (heightened expression) of cell surface urokinase-type plasminogen activator receptor (urokinase receptor) compared to normal (non-cancerous) cells. The compounds preferably covalently bind to the urokinase receptor and recruit native antibodies of the patient or subject where the antibodies can selectively degrade and/or deactivate targeted cancer cells through antibody-dependent cellular phagocytosis and/or antibody-dependent cellular cytotoxicity (ADCC) against a large number and variety of cancers, thus providing cancer cell death and/or an inhibition of growth, elaboration and/or metastasis of the cancer, including remission and cure of the patient's cancer.Type: ApplicationFiled: November 7, 2012Publication date: October 16, 2014Inventors: David A. Spiegel, Charles E. Jakobsche
-
Publication number: 20140302173Abstract: A method for treating side effects of anticancer agent includes administering to a subject in need thereof a prophylactic and/or therapeutic agent containing a therapeutically effective amount of a compound shown by the following Formula (1): R1—NHCH2COCH2CH2COOR2 ??(I) wherein R1 represents a hydrogen atom or an acyl group, and R2 represents a hydrogen atom, a linear or branched alkyl group, a cycloalkyl group, an aryl group, or an aralkyl group, or a salt thereof.Type: ApplicationFiled: October 5, 2012Publication date: October 9, 2014Applicants: NATIONAL UNIVERSITY CORPORATION KOCHI UNIVERSITY, SBI PHARMACEUTICALS CO., LTD.Inventors: Tohru Tanaka, Kyoko Tsuchiya, Masahiro Ishizuka, Motowo Nakajima, Hitoshi Nakagawa, Taro Shuin, Keiji Inoue, Hideo Fukuhara, Masayuki Tsuda, Mutsuo Furihata
-
Publication number: 20140302174Abstract: The present invention provides a method of treating ovarian cancer in a mammal in need of such treatment comprising administering an effective amount of a combination of gemcitabine, cisplatin or carboplatin, and 5-[2-tert-butyl-5-(4-fluoro-phenyl)-1H-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine.Type: ApplicationFiled: October 31, 2012Publication date: October 9, 2014Inventors: Edward Michael Chan, Susan Elizabeth Pratt, Louis Frank Stancato
-
Publication number: 20140301976Abstract: The present invention is directed to certain hydroxamate derivatives that are useful in the treatment of hepatitis C. These compounds are also inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositions and processes for preparing these compounds are also disclosed.Type: ApplicationFiled: June 20, 2014Publication date: October 9, 2014Inventors: Erik J. VERNER, Martin SENDZIK, Chitra BASKARAN, Joseph J. BUGGY, James ROBINSON
-
Publication number: 20140301951Abstract: Various exemplary embodiments provide protocell nanostructures and methods for constructing and using the protocell nanostructures. In one embodiment, the protocell nanostructures can include a core-shell structure including a porous particle core surrounded by a shell of lipid bilayer(s). The protocell can be internalized in a bioactive cell. Various cargo components, for example, drugs, can be loaded in and released from the porous particle core of the protocell(s) and then delivered within the bioactive cell.Type: ApplicationFiled: April 15, 2014Publication date: October 9, 2014Inventors: Juewen Liu, C. Jeffrey Brinker, Carlee Ashley, Eric C. Carnes
-
Publication number: 20140302010Abstract: The present invention relates to substituted benzimidazole compounds of general formula (I) in which R3, R5 and A are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: March 28, 2012Publication date: October 9, 2014Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Ulrich Klar, Marcus Koppitz, Duy Nguyen, Dirk Kosemund, Roland Neuhaus, Gerhard Siemeister
-
Publication number: 20140302172Abstract: The present invention relates to a method for predicting the responsiveness of a mammalian tumor cell or cancer cell to an inhibitor of a kinase of the Src family, such as dasatinib, bosutinib, saracatinib or ponatinib. The present invention also provides for a method for predicting the responsiveness of an individual to an inhibitor of a kinase of the Src family, whereby the individual is suspected to suffer from cancer. These methods involve the evaluation of the status of integrin ?4, wherein said status is indicative for the responsiveness to the inhibitor. Furthermore, a kit useful for carrying out the methods described herein as well as an oligo- or polynucleotide and/or antibodies capable of detecting the expression level of integrin ?4 for predicting the responsiveness to the inhibitor are provided.Type: ApplicationFiled: August 16, 2012Publication date: October 9, 2014Inventors: Christoph Schaab, Klaus Godl, Martin Klammer, Andreas Tebbe, Stefan Müller
-
Publication number: 20140296836Abstract: The present invention provides methods and compositions for the nanotechnology-based therapy of one or more mammalian diseases. Disclosed are gold-in-porous silicon nanoassemblies that are effective in the targeted and localized treatment of one or more human hyperproliferative disorders, including, for example, cancer of the breast. Methods of systemic administration of these nanoassembly vectors are disclosed that facilitate direct thermal ablative therapy of selected tissues using a localized application of near-infrared energy to the target site, wherein the gold-in-porous silicon nanoparticles release heat to destroy the surrounding cancerous tissue.Type: ApplicationFiled: March 27, 2014Publication date: October 2, 2014Applicants: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, THE METHODIST HOSPITAL RESEARCH INSTITUTEInventors: Haifa SHEN, Mauro Ferrari, Chun Li, Jian You